Oruka Therapeutics, Inc (ORKA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Oruka Therapeutics, Inc (ORKA) is up 82.2% since the beginning of the year. At $55 per share, ORKA is trading 39.3% below its 52-week high of $91. Investors who bought $1,000 worth of ORKA shares 5 years ago would now be looking at an investment worth $2,326.

Oruka Therapeutics, Inc (ORKA) has returned 82.22% so far this year and 362.56% over the past 12 months. Over the last ten years, ORKA has returned -17.59% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Aug 8, 1997, ORKA's average daily return is +0.09%, while the average monthly return is +0.97%. At this rate, an investment would double in approximately 6.0 years.

Historically, 44% of months were positive and 56% were negative. The best month was May 2020 with a return of +244.3%, while the worst month was Dec 2006 at -79.2%. The longest winning streak lasted 14 consecutive months, and the longest losing streak was 15 months.

On a daily basis, ORKA closed higher 42% of trading days. The best single day was May 28, 2020 with a return of +386.3%, while the worst single day was Dec 11, 2006 at -79.3%.

Oruka Therapeutics, Inc has an annualized alpha of 16.88%, beta of 0.76, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 11, 1997.

• This stock participated in 190.28% of S&P 500 Index downside but only 38.91% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ORKA ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Oruka Therapeutics, Inc (ORKA) and compare them to S&P 500 Index.

Oruka Therapeutics, Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Oruka Therapeutics, Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Oruka Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Oruka Therapeutics, Inc was 100.00%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Oruka Therapeutics, Inc drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Oruka Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Oruka Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.